Securing Biopharmaceutical Supply Chains

(gentle music begins)

- [Narrator] The coronavirus pandemic,

the great power competition, wide area wildfires,

and other major events heighten the vulnerabilities

in our nation's bio-pharmaceutical supply chains.

Securing and diversifying these supply chains

is not just a matter of public health and well-being.

It's vital to our national security.

We need to strengthen the safety and security

of basic life-saving

and specialized medicines and equipment.

Weaknesses at any point in this critical infrastructure

threaten the whole system.

Shortages in any one area puts lives at risk.

- What we're finding is that we have a shortage triggered,

in large part exacerbated by the COVID-19 pandemic,

that 29 out of 40 critical drugs

that are required to preserve and protect and save lives

are now in critical shortage.

Unlike any other threat that we prepare for as a nation,

nuclear threat, cyber attack, others,

this is a near-simultaneous global event.

- [Narrator] Industrial-based policy

and innovative business models are needed

to realign incentives and enable requisite production

to strengthen the bioeconomy

and achieve national security objectives.

- There's a need right now

for the strengths and the capabilities that MITRE brings.

Again, our systems thinking,

our deep expertise in supply chain risk management,

our understanding and the trusted relationships

we've established with the bio-pharmaceutical industry,

to be a neutral, independent arbiter,

understanding that there are differences

between the public health and the industrial communities.

- [Narrator] Developing solutions

to secure bio-pharmaceutical supply chains

is part of MITRE's mission of solving problems

for a safer world.

(gentle music ends)